562-10-7 Doxylamine Succinate 99%

Established as one of the leading names in API manufacturing and intermediates, BioXera Pharma specialises in the development of innovative processes for a wide range of products. The business comprises of manufacture and sales of APIs and intermediates in both domestic and international markets, including the regulated markets. With a strong R&D, technology, word class infrastructure, headed by a team of technocrats, BioXera has established a large portfolio of molecules in the commercial production along with several more in the pipeline.

With the ability to handle complex chemical synthesis, BioXera has built up strength in the development, process optimisation and cGMP production of APIs and intermediates. At BioXera, in every aspect of work, quality assurance is an attitude of seeking sustainable betterment. Today BioXera offers API and intermediates to over 13 countries, and are poised to enter more shortly.